Dialysis firm sees positive revenue growth ahead

Citing a growing patient pool and an expansion of offerings into kidney failure-related medical fields, Fresenius Medical Care (FMS +2.6%) forecasts its top line to double to $28B by 2020.

The number of global dialysis patients should grow 6.3%/year, slightly lower than the 6.8% rate over the past 13 years.

The company believes it is well-positioned to take advantage of the transition from payments for individual services to lump-sum payments per dialysis session.

(DVA +0.3%)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs